TORONTO, ON--(Marketwired - Sep 9, 2013) - Axxess Pharma Inc. (PINKSHEETS: AXXE), a specialty pharmaceutical and nutritional supplements company, is pleased to announce they have signed an agreement with a leading Mexican pharmaceutical company, Industria Farmaceutica Andromaco, S.A. de C.V.
Under the agreement, Axxess Pharma's product, Soropon, will be marketed in Mexico by Andromaco. Axxess has also secured the rights to market in Canada, several of Andromaco's market leading baby-care products.
Axxess's Soropon, a medicated shampoo for the treatment of cradle cap in infants and a severe form of dandruff in seniors (Seborrheic dermatitis), fits with Andromaco's core product line and is anticipated to generate strong sales.
Dr. Daniel Bagi, President of Axxess Pharma, stated: "With a population three times that of Canada's and a higher birth rate than Canada's, Axxess is extremely pleased with the market possibilities in Mexico for Soropon and we anticipate robust sales for Soropon in Mexico, starting in 2014. Two of Andromaco's baby care products are among the market leaders in Mexico with annual sales in excess of ten million dollars (US). Andromaco also generates sales exporting and selling into the US. These products are manufactured in Andromaco's US FDA-approved facility. Their product offerings in infant skin care will add to our OTC infant skincare product line for the Canadian market."
Mr. Víctor Álvarez, CEO of Andromaco, stated: "Andromaco is very pleased to start the process towards Canadian sales with Axxess Pharma for our high-quality infant care products and complete our goal of selling all across North America."
For more information, please visit www.axxesspharmainc.com, or contact Investor Relations at (973) 351-3868.
About Axxess Pharma Inc.:
Axxess Pharma Inc. is a Nevada Corporation operating through its wholly-owned Canadian Subsidiary: Axxess Pharma Canada Inc., headquartered in Toronto. Axxess is a specialty Health Care Products Company dedicated to improving health and quality of life by offering select medicines, nutritional supplements and over the counter remedies all across the Americas. Axxess's goal is to bring additional products to the market and provide new, innovative options for better health spanning areas such as high cholesterol, blood pressure, acute pain, to optimal health management through improved nutritional supplements.
Industria Farmaceutica Andromaco, S.A. de C.V.
Andromaco is a well-established Mexican pharmaceutical company with over 80 years in the Mexican market. They have a US FDA-approved state-of-the-art manufacturing facility for creams and ointments and are one of the top 10 Mexican pharmaceutical manufacturers.
Safe Harbor Statement:
Statements about the Company's future expectations and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby.
The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management, as well as assumptions made by any information currently available to the Company or its management. When used in this document, the words "anticipate," "estimate," "expect," "intend," "plans," "projects," and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. Such statements reflect the current view of the Company regarding future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties noted. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove to be incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, expected, intended or projected. In each instance, forward-looking information should be considered in light of the accompanying meaningful cautionary statements herein. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, the impact of competitive services and pricing and general economic risks and uncertainties.